NICE deems breast cancer drug not cost effective
The National Institute for Health and Care Excellence (NICE) has announced that it does not find everolimus cost effective. The breast cancer treatment, aslo known as Afinitor and manufactured by Novartis Pharmaceuticals, will therefore not be recommended for use by the NHS.
The guidance advises that the treatment should not be routinely provided as a treatment for postmenopausal women with HER2 negative, hormone-receptor-positive advanced breast cancer.
Whilst the treatment was acknowledged to delay the growth and spread of breast cancer by around four months, there were uncertainties relating to how long it could extend a person’s life compared with the drug exemestane (Aromasin®) alone.
Women who are already receiving everolimus should continue with it until they and their doctor thinks it’s appropriate to stop, according to the guidance.
‘Breast cancer drug not cost-effective’, says NICE (NICE press release)
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.